Drug class
Somatostatin analogue; DTPA-conjugated peptide radiopharmaceutical ligand
Mechanism of action
The pentetreotide peptide moiety binds somatostatin receptors, particularly subtype 2, expressed on many neuroendocrine tumour cells. When conjugated with indium-111, the radiolabel enables scintigraphic localisation of somatostatin-receptor-positive lesions.
General use cases
- Used as the peptide component of indium In-111 pentetreotide (octreotide DTPA) for scintigraphic imaging of somatostatin-receptor-positive neuroendocrine tumours; the radiolabelled product, not unlabelled pentetreotide alone, is the diagnostic radiopharmaceutical.
For general informational purposes only. Do not rely on, cross-reference, cite or use this information as evidence or support for legal, regulatory, commercial or other claims.
